DE60103137D1 - Impstoff zur behandlung von atherosclerosis - Google Patents

Impstoff zur behandlung von atherosclerosis

Info

Publication number
DE60103137D1
DE60103137D1 DE60103137T DE60103137T DE60103137D1 DE 60103137 D1 DE60103137 D1 DE 60103137D1 DE 60103137 T DE60103137 T DE 60103137T DE 60103137 T DE60103137 T DE 60103137T DE 60103137 D1 DE60103137 D1 DE 60103137D1
Authority
DE
Germany
Prior art keywords
atherosclerosis
vaccine
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60103137T
Other languages
English (en)
Other versions
DE60103137T2 (de
Inventor
Jean-Charles Fruchart
Philippe Monteyne
Remi Palmantier
Mechelen Paulette Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0005240A external-priority patent/GB0005240D0/en
Priority claimed from GB0022005A external-priority patent/GB0022005D0/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of DE60103137D1 publication Critical patent/DE60103137D1/de
Application granted granted Critical
Publication of DE60103137T2 publication Critical patent/DE60103137T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0012—Lipids; Lipoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
DE60103137T 2000-03-03 2001-03-01 Impstoff zur behandlung von atherosclerosis Expired - Fee Related DE60103137T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0005240A GB0005240D0 (en) 2000-03-03 2000-03-03 Vaccine
GB0005240 2000-03-03
GB0022005A GB0022005D0 (en) 2000-09-07 2000-09-07 Vaccine
GB0022005 2000-09-07
PCT/EP2001/002326 WO2001064008A2 (en) 2000-03-03 2001-03-01 Vaccine for the treatment of artherosclerosis

Publications (2)

Publication Number Publication Date
DE60103137D1 true DE60103137D1 (de) 2004-06-09
DE60103137T2 DE60103137T2 (de) 2005-05-25

Family

ID=26243793

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60103137T Expired - Fee Related DE60103137T2 (de) 2000-03-03 2001-03-01 Impstoff zur behandlung von atherosclerosis

Country Status (19)

Country Link
US (1) US20030165503A1 (de)
EP (1) EP1267908B1 (de)
JP (1) JP2003525883A (de)
KR (1) KR20020079983A (de)
CN (1) CN1418106A (de)
AR (1) AR027591A1 (de)
AT (1) ATE265860T1 (de)
AU (1) AU2001246493A1 (de)
BR (1) BR0108924A (de)
CA (1) CA2401755A1 (de)
CZ (1) CZ20022971A3 (de)
DE (1) DE60103137T2 (de)
ES (1) ES2219517T3 (de)
HU (1) HUP0300099A3 (de)
IL (1) IL151355A0 (de)
MX (1) MXPA02008616A (de)
NO (1) NO20024172L (de)
PL (1) PL365424A1 (de)
WO (1) WO2001064008A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110590937A (zh) * 2018-06-13 2019-12-20 杨宝田 一种人血载脂蛋白a1制品的制备方法及应用

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121171D0 (en) * 2001-08-31 2001-10-24 Glaxosmithkline Biolog Sa Vaccine
IL149379A0 (en) * 2000-09-04 2002-11-10 Hyo Joon Kim Mimetic peptides for epitope of apolipoprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
JP2005502029A (ja) * 2001-06-05 2005-01-20 ジェンフィ アポｂおよび非アポｂ含有粒子中のアポｃｉｉｉを測定する新規な方法
EP1438060B1 (de) 2001-09-28 2015-11-11 Esperion Therapeutics Inc. Prävention und behandlung von restenose durch lokale verabreichung eines arzneimittels
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
WO2004030607A2 (en) * 2002-10-04 2004-04-15 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302312D0 (sv) 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
GB0305794D0 (en) * 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Vaccine
GB0305790D0 (en) * 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Novel Composition
GB0305793D0 (en) * 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Vaccine
GB2404981A (en) * 2003-08-15 2005-02-16 Univ Geneve Diagnostic method for stroke
KR100639397B1 (ko) * 2004-03-18 2006-10-26 (주)에스제이바이오메드 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
EP1732383A4 (de) 2004-04-06 2007-05-02 Cedars Sinai Medical Center Vorbeugung und behandlung von gefässerkrankungen mit rekombinanten adeno assoziierten virusvektoren, die für apolipoprotein a-i und apolipoprotein a-i milano kodieren
JP2008538812A (ja) * 2005-04-11 2008-11-06 アストラゼネカ アクチボラグ 方法
WO2009152493A2 (en) * 2008-06-13 2009-12-17 The General Hospital Corporation Use of apolipoproteins to decrease inflammation
CU23736A1 (es) 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
US8506964B2 (en) 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
RU2013126626A (ru) 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер Иммуномодулирующие способы и системы для лечения и/или предотвращения гипертензий
RU2013126628A (ru) 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер Иммуномодулирующие способы и системы для лечения и/или предотвращения аневризм
WO2014131008A1 (en) * 2013-02-25 2014-08-28 Intrinsic Metabio Solutions, Llc A polipoprotein c3 (apociii) antagonists and methods of their use to remove apociii inhibition of lipoprotein lipase (lpl)
CN103520713B (zh) * 2013-10-16 2015-10-28 西北农林科技大学 一种ApoB100酵母重组疫苗及其制备方法和应用
CN114085283A (zh) * 2015-05-19 2022-02-25 拉·约拉过敏反应及免疫医学研究所 调节炎症应答及治疗不良心血管事件、病和粥样硬化的人apob100表位、方法和用途
CN106810606A (zh) * 2015-11-27 2017-06-09 西藏自治区人民医院 一种载脂蛋白c-ⅲ抗原多肽及其多克隆抗体的制备与应用
WO2017205454A1 (en) * 2016-05-24 2017-11-30 Bryce Chackerian Immunogens, compositions, and methods for treating dyslipidemia
MA45602A (fr) 2016-07-08 2019-05-15 Staten Biotechnology B V Anticorps anti-apoc3 et leurs méthodes d'utilisation
CN106519007B (zh) * 2016-12-12 2019-07-02 王家祥 一种单链多肽及其在制备用于预防和治疗胃癌的药物中的应用
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
CA3080103A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
WO2022136466A1 (en) 2020-12-23 2022-06-30 Argonaute RNA Limited Treatment of cardiovascular disease
WO2023041508A2 (en) 2021-09-14 2023-03-23 Argonaute RNA Limited Treatment of cardiovascular disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002062A1 (en) * 1985-10-04 1987-04-09 Biotechnology Research Partners, Ltd. Recombinant apolipoproteins and methods
WO1993000443A1 (en) * 1991-06-26 1993-01-07 Bio-Technology General Corp. Purification of recombinant apolipoprotein e from bacteria
IL104015A0 (en) * 1992-12-07 1993-05-13 Doina International Ltd P Method for immunization of mammals against atherosclerosis and pharmaceutical compositions for obtaining said immunization
EP0934337B1 (de) * 1996-08-23 2007-12-19 Esperion Therapeutics Inc. Verfahren zur aufreinigung von apolipoprotein-a oder apolipoprotein-e aus menschlichem plasma
US6492185B1 (en) * 1998-01-16 2002-12-10 Abbott Laboratories Immunoassay for detection of very low density lipoprotein and antibodies useful therefor
FR2776388B1 (fr) * 1998-03-20 2006-04-28 Lipha Utilisation de recepteurs de la famille ror pour le criblage de substances utiles pour le traitement de l'atherosclerose
FR2780512B1 (fr) * 1998-06-25 2003-10-17 Lipha Utilisation de recepteurs de la famille rev-erb pour le criblage de substances utiles dans le traitement des dysfonctionnements du metabolisme lipidique

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110590937A (zh) * 2018-06-13 2019-12-20 杨宝田 一种人血载脂蛋白a1制品的制备方法及应用

Also Published As

Publication number Publication date
US20030165503A1 (en) 2003-09-04
EP1267908B1 (de) 2004-05-06
IL151355A0 (en) 2003-04-10
ES2219517T3 (es) 2004-12-01
ATE265860T1 (de) 2004-05-15
NO20024172D0 (no) 2002-09-02
CA2401755A1 (en) 2001-09-07
AU2001246493A1 (en) 2001-09-12
JP2003525883A (ja) 2003-09-02
WO2001064008A2 (en) 2001-09-07
CN1418106A (zh) 2003-05-14
CZ20022971A3 (cs) 2003-02-12
BR0108924A (pt) 2003-04-29
EP1267908A1 (de) 2003-01-02
HUP0300099A3 (en) 2004-10-28
WO2001064008A3 (en) 2002-02-14
PL365424A1 (en) 2005-01-10
MXPA02008616A (es) 2003-02-24
KR20020079983A (ko) 2002-10-21
HUP0300099A2 (en) 2003-05-28
NO20024172L (no) 2002-11-01
DE60103137T2 (de) 2005-05-25
AR027591A1 (es) 2003-04-02

Similar Documents

Publication Publication Date Title
DE60103137D1 (de) Impstoff zur behandlung von atherosclerosis
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60035378D1 (de) Gerät zur Behandlung von Bandscheiben
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE323661T1 (de) Behandlung von mineralischen stoffen
ATE451921T1 (de) Phenylindole zur behandlung von hiv
ATE538096T1 (de) Pyridinon-derivate zur behandlung von arteriosklerose
DE60138129D1 (de) Apparat zur behandlung von zähnen
DE60114808D1 (de) Oberflächenbehandlung von medizinischer vorrichtung
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE60030554T8 (de) Verwendungen von et743 zur behandlung von krebs
DE60114439D1 (de) Verfahren zur antimikrobiellen behandlung von fasermaterialien
ATE254913T1 (de) Diacerein zur behandlung von psoriasis
DE60104791D1 (de) Cyclobutendion-Derivate zur Behandlung von Artherosclerose
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE69737067D1 (de) Vakzine zur behandlung von mycosen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60006412D1 (de) Oxazinochinolone zur behandlung von viralen infektionen
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen
DE60103685D1 (de) Behandlung von Poriomania

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee